These changes included the downregulation of SOCS3, a positive regulator of cytokine signaling (24), Muc1, whose overexpression is associated with IBD (25) and S100a8, a component of the calprotectin complex and a clinical marker for IBD (26) (Figure S8 in Supplementary Material). Here, MUC1 is linked to inflammatory bowel disease.